16:37 EDT Eton Pharmaceuticals (ETON) sees reaching annual revenue run rate of $80M in Q3
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals’ ET-600 Launch and Strategic Expansion Drive Buy Rating
- Eton Pharmaceuticals’ New Drug Application Accepted by FDA
- Eton Pharmaceuticals’ NDA for ET-600 solution accepted by FDA
- Eton Pharmaceuticals management to meet with B. Riley
- Eton Pharmaceuticals Joins Russell 3000 and 2000 Indexes